抗凝治疗的移植患者尿液中的纤维蛋白溶解降解产物
Fibrinolytic degradation products in urine of anticoagulated transplant patients.
作者信息
Aguilo J J, Bowie E J, Woods J E, Owen C A
出版信息
Eur Urol. 1978;4(1):46-9. doi: 10.1159/000473906.
A study of the level of urinary fibrinolytic split products in 14 renal transplant patients who received oral anticoagulants postoperatively revealed a tendency toward increased levels of fibrinolytic split products that were temporally related to graft rejection. The amount of fibrinolytic split products in the urine was positively related to the severity of rejection as well as to the final status of the allograft. Thus, the urinary level of fibrinolytic split products, as determined by the latex-coated particle test, can be used as an indicator of the course of warfarin-anticoagulated patients after renal allografting.
一项针对14名肾移植患者的研究发现，这些患者术后接受口服抗凝剂治疗，其尿中纤维蛋白溶解分裂产物水平有升高趋势，且在时间上与移植排斥反应相关。尿中纤维蛋白溶解分裂产物的量与排斥反应的严重程度以及同种异体移植物的最终状态呈正相关。因此，通过乳胶包被颗粒试验测定的尿中纤维蛋白溶解分裂产物水平，可作为肾移植后接受华法林抗凝治疗患者病程的一个指标。
Zotero 插件